title: Combined therapy of parkinsonism in experiment
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: ÐÐ¾Ð¼Ð±Ð¸Ð½Ð¸ÑÐ¾Ð²Ð°Ð½Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ Ð¿Ð°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð¸Ð·Ð¼Ð° Ð² ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐµ
Creators: name: ÐÑÑÐµÐ¼Ð¾Ð²Ð°, ÐÐ°Ð»ÐµÑÐ¸Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: ÐºÐ°Ð»ÑÐ¿Ð°Ð¸Ð½-1
ÐºÐ°Ð»ÑÐ¿Ð°Ð¸Ð½-2
ÐÐ¤Ð¢Ð
Ð¾ÑÐºÑÑÑÐ¾Ðµ Ð¿Ð¾Ð»Ðµ
ÑÐµÑÑ Â«ÑÐµÑÑÂ»
Ð£Ð ÐÐ
ÑÐµÑÑ Â«ÑÐ¸Ð»Ð¸Ð½Ð´ÑÂ»
ÐºÐ°Ð»ÑÐ¿Ð°ÑÑÐ°ÑÐ¸Ð½
Ð-ÐÐÐ¤Ð
calpain-1
calpain-2
MPTP
open field
âpoleâ test
active avoidance
âcylinderâ test
CAST
L-DOPA

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ Ð¾ÑÐ¾Ð±ÐµÐ½Ð½Ð¾ÑÑÐµÐ¹ Ð¿Ð¾Ð²ÐµÐ´ÐµÐ½Ð¸Ñ ÐºÑÑÑ Ð¿ÑÐ¸ Ð¸Ð½Ð´ÑÐºÑÐ¸Ð¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° Ð¸ Ð² ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð»ÐµÑÐµÐ½Ð¸Ñ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¿Ð¾Ð²ÐµÐ´ÐµÐ½ÑÐµÑÐºÐ¸Ñ ÑÐµÑÑÐ¾Ð²: Â«ÐÑÐºÑÑÑÐ¾Ðµ Ð¿Ð¾Ð»ÐµÂ», Â«Ð¨ÐµÑÑÂ», Â«Ð£Ð ÐÐÂ», Â«Ð¦Ð¸Ð»Ð¸Ð½Ð´ÑÂ». Ð¦ÐµÐ»Ñ ÑÐ°Ð±Ð¾ÑÑ: Ð¾ÑÐµÐ½Ð¸ÑÑ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ ÐºÐ¾Ð¼Ð±Ð¸Ð½Ð¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ (Ð-ÐÐÐ¤Ð+Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾Ñ ÐºÐ°Ð»ÑÐ¿Ð°Ð¸Ð½Ð¾Ð² 1 Ð¸ 2 CAST) Ð½Ð° Ð¼Ð¾ÑÐ¾ÑÐ½ÑÐµ Ð¸ ÐºÐ¾Ð³Ð½Ð¸ÑÐ¸Ð²Ð½ÑÐµ ÑÑÐ½ÐºÑÐ¸Ð¸ ÐºÑÑÑ Ð² Ð¼Ð¾Ð´ÐµÐ»Ð¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°. ÐÐ°Ð´Ð°ÑÐ¸, ÐºÐ¾ÑÐ¾ÑÑÐµ ÑÐµÑÐ°Ð»Ð¸ÑÑ Ð² ÑÐ¾Ð´Ðµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ: 1. ÐÐ¿ÑÐµÐ´ÐµÐ»Ð¸ÑÑ Ð²ÑÑÐ°Ð¶ÐµÐ½Ð½Ð¾ÑÑÑ Ð´Ð²Ð¸Ð³Ð°ÑÐµÐ»ÑÐ½ÑÑ Ð¸ ÐºÐ¾Ð³Ð½Ð¸ÑÐ¸Ð²Ð½ÑÑ Ð½Ð°ÑÑÑÐµÐ½Ð¸Ð¹ Ñ ÐºÑÑÑ Ð¿Ð¾ÑÐ»Ðµ Ð¾Ð´Ð½Ð¾ÐºÑÐ°ÑÐ½Ð¾Ð³Ð¾ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ñ ÐÐÐ¢Ð Ð² Ð´Ð¾Ð·Ðµ 0,0025 Ð¼Ð³; 2. ÐÐ¿ÑÐµÐ´ÐµÐ»Ð¸ÑÑ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ ÑÐ¾ÑÐµÑÐ°Ð½Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð-ÐÐÐ¤Ð+CAST Ð½Ð° Ð´Ð²Ð¸Ð³Ð°ÑÐµÐ»ÑÐ½ÑÐµ ÑÑÐ½ÐºÑÐ¸Ð¸ ÐºÑÑÑ; 3. ÐÐ¿ÑÐµÐ´ÐµÐ»Ð¸ÑÑ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ ÑÐ¾ÑÐµÑÐ°Ð½Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð-ÐÐÐ¤Ð+CAST Ð½Ð° ÐºÐ¾Ð³Ð½Ð¸ÑÐ¸Ð²Ð½ÑÐµ ÑÑÐ½ÐºÑÐ¸Ð¸ ÐºÑÑÑ. Ð Ð°Ð±Ð¾ÑÐ° Ð±ÑÐ»Ð° Ð²ÑÐ¿Ð¾Ð»Ð½ÐµÐ½Ð° Ð² ÐÐ°Ð±Ð¾ÑÐ°ÑÐ¾ÑÐ¸Ð¸ Ð½ÐµÐ¹ÑÐ¾ÑÐ¸Ð¼Ð¸Ð¸ Ð¤Ð¸Ð·Ð¸Ð¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð¾ÑÐ´ÐµÐ»Ð° Ð¸Ð¼. Ð.Ð. ÐÐ°Ð²Ð»Ð¾Ð²Ð° Ð¤ÐÐÐÐ£ ÐÐ­Ð. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð¿ÑÐ¾Ð´ÐµÐ»Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ»Ð¾ Ð²ÑÑÑÐ½ÐµÐ½Ð¾, ÑÑÐ¾: 1. ÐÐ´Ð½Ð¾ÐºÑÐ°ÑÐ½Ð¾Ðµ Ð¸Ð½ÑÑÐ°ÑÐµÑÐµÐ±ÑÐ°Ð»ÑÐ½Ð¾Ðµ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ðµ ÐÐ¤Ð¢Ð Ð² Ð´Ð¾Ð·Ð¸ÑÐ¾Ð²ÐºÐµ 0,0025 Ð¼Ð³ Ð¿ÑÐ¸Ð²Ð¾Ð´Ð¸Ñ Ðº Ð²Ð¸Ð´Ð¸Ð¼ÑÐ¼ Ð´Ð²Ð¸Ð³Ð°ÑÐµÐ»ÑÐ½ÑÐ¼ Ð¸ ÐºÐ¾Ð³Ð½Ð¸ÑÐ¸Ð²Ð½ÑÐ¼ Ð½Ð°ÑÑÑÐµÐ½Ð¸ÑÐ¼; 2. Ð´Ð¾Ð±Ð°Ð²Ð»ÐµÐ½Ð¸Ðµ ÐºÐ°Ð»ÑÐ¿Ð°ÑÑÐ°ÑÐ¸Ð½Ð° Ðº ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð² Ð´Ð¾Ð·Ð¸ÑÐ¾Ð²ÐºÐµ 5 Ð¼ÐºÐ³/ÐºÐ³ Ð² Ð´Ð¾Ð¿Ð¾Ð»Ð½ÐµÐ½Ð¸Ðµ Ðº Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ñ Ð-ÐÐÐ¤Ð Ð² ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸Ð¸ 100 Ð¼Ð³/ÐºÐ³ Ð½Ðµ Ð¿ÑÐ¸Ð²Ð¾Ð´Ð¸Ñ Ðº ÑÐ»ÑÑÑÐµÐ½Ð¸Ñ Ð´Ð²Ð¸Ð³Ð°ÑÐµÐ»ÑÐ½ÑÑ ÑÑÐ½ÐºÑÐ¸Ð¹; 3. ÑÐ¾Ð³Ð»Ð°ÑÐ½Ð¾ ÑÐµÑÑÑ, "ÐÐºÑÐ¸Ð²Ð½Ð¾Ðµ Ð¸Ð·Ð±ÐµÐ³Ð°Ð½Ð¸Ðµ", Ð´Ð¾Ð±Ð°Ð²Ð»ÐµÐ½Ð¸Ðµ ÐºÐ°Ð»ÑÐ¿Ð°ÑÑÐ°ÑÐ¸Ð½Ð° Ðº ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð¿ÑÐ¸Ð²Ð¾Ð´Ð¸Ñ Ðº Ð·Ð°Ð¼ÐµÑÐ½Ð¾Ð¼Ñ ÑÐ»ÑÑÑÐµÐ½Ð¸Ñ ÐºÐ¾Ð³Ð½Ð¸ÑÐ¸Ð²Ð½ÑÑ ÑÑÐ½ÐºÑÐ¸Ð¹.
description: This work is devoted to the study of the behavior of rats during the induction of Parkinsons disease and as a result of treatment using tests: "Open field", "Pole", "Active avoidance", "Cylinder". Objective: to evaluate the effect of combination therapy (L-DOPA + calpain inhibitor 1 and 2 CAST) on the motor and cognitive functions of rats in a model of Parkinsons disease. Tasks that were solved during the study: 1. To identify motor changes during the induction of Parkinsons Disease and as a result of treatment; 2. To identify cognitive changes during the induction of Parkinsons Disease and as a result of treatment; 3. According to the results of the study, to propose a potential scheme for the use of calpastatin in the therapy of Parkinsons Disease. The work was carried out in the Laboratory of Neurochemistry, I.P. Pavlov Department of Physiology of Federal State Budgetary Scientific Institution âInstitute of Experimental Medicineâ. As a result of the work done, it was found out: 1. single intracerebral injection of MPTP at a dosage of 0.0025 mg leads to visible motor and cognitive impairments; 2. the addition of calpastatin to therapy at a dosage of 5 Î¼g / kg in addition to the administration of L-DOPA at a concentration of 100 mg / kg does not lead to an improvement in motor functions; 3. according to the "Active Avoidance" test, the addition of calpastatin to therapy leads to a visible improvement in cognitive functions.